Ticker brief · 2026-07-03
TEM TEMPUS AI INC-CL A
Breakout bulls dominate, but quality skepticism remains
Consumer, Non-cyclical · Healthcare-Products
Lean: bullishlast close
$60.27
1 day
-2.2%
14 days
+18.5%
mkt cap
$10.8B
signals 14d
183
authors 14d
83
TEM skew is bullish, led by a crowded technical breakout tape and a broader AI healthcare/data-moat thesis. The late-week shift was from entry calls toward scale-outs, cash-secured put selling, and risk controls after the move through $60. Trade structure implies momentum holders are still leaning long, but upside is increasingly dependent on holding the breakout rather than fresh fundamental proof.
BULL CAMP
Bulls argue TEM has transitioned from a beaten-down AI healthcare name into a confirmed breakout with room toward $70-$75. The stronger version of the case pairs price action with a proprietary health-data moat, pharma partnerships, and sector rotation into genomics/healthcare.
Key voices@IncomeSharksMEDIUM-HIGHB-0.60@MMMTwealthMEDIUM-HIGHA+1.97@SRxTradesMEDIUM-HIGHC+0.35@MarketMaestro1MEDIUM-HIGHC-1.27@RosannaInvestsMEDIUMB+0.07
“TEM broke past 60 with resistance not until the 75 range, extending the breakout setup.”— @IncomeSharks · tweet ↗
BEAR / SKEPTIC
Bear voices are narrower but higher-signal: one challenges the scientific substance of prior research, one flags insider Form 4 selling, and Freedom Capital's Hold with $59 PT tempers upside. This is not a broad short thesis, more a quality and valuation check after a fast run.
Key voices“Prior TEM research was unimpressive and CEO comments did not make scientific sense.”— @SixSigmaCapital · tweet ↗
Hypotheses9direction · basis · magnitude · supporters — NEW = first seen this week
▲TEM confirmed a technical breakout above 54-60, with momentum targets clustering around 63-75 if the breakout holds.
@enrichtradesMEDIUMC-1.644s@Volume_StocksMEDIUMC-2.803s@MarketMaestro1MEDIUM-HIGHC-1.274s@IncomeSharksMEDIUM-HIGHB-0.604s · insight@mark_to_mktMEDIUMC-3.454s@upsidetraderMEDIUMC-1.124s+8 more
▲Tempus should rerate as an AI healthcare platform with proprietary health data, pharma partnerships, and precision-medicine leverage.
@MisterInversorMEDIUMC-0.575s@RosannaInvestsMEDIUMB+0.071s · insight@Abim4el_CarlosLOWC-4.092s@gabz_investingMEDIUMC+0.061s@JoshTradeOptionLOW-MEDIUMC+0.821s@MMMTwealthMEDIUM-HIGHA+1.971s · insight+3 more
▲Healthcare, biotech, and genomics rotation is lifting TEM as investors seek AI-enabled defensive growth away from weaker tape.
@DonDrapperrMEDIUMB+0.401s@SRxTradesMEDIUM-HIGHC+0.352s@IncomeSharksMEDIUM-HIGHB-0.602s · insight@davevermilionMEDIUM-HIGHA-2.031s · insight@MisterInversorMEDIUMC-0.573s@WealthyReadingsMEDIUM-HIGHB-0.621s · insight+1 more
▲High short interest, ARKG exposure, and bullish options flow can amplify TEM upside if momentum persists.
@enrichtradesMEDIUMC-1.641s@OptionsFlowBossLOW-MEDIUMC2s@ZaStocksMEDIUM-HIGHC-0.551s@Micro2Macr0MEDIUM-HIGHC-1.261s@Sir_KoryLOW-MEDIUMC+1.611s@StratsLabsMEDIUM-HIGHC+2.191s
▼Freedom Capital's Hold initiation with a $59 PT limits near-term upside after TEM's rally.
@AIStockSavvyMEDIUMC+0.051s
▼TEM's scientific and research foundation may be weaker than bulls assume, with prior work and CEO comments criticized.
@SixSigmaCapitalMEDIUM-HIGHB-0.482s · insight
▼A Form 4 filing by Eric Lefkofsky creates insider-selling overhang after the late-June TEM run.
@OpenOutcrierMEDIUM-HIGHC1s
◆After the fast move, some traders are scaling out, exiting, or enforcing stops rather than adding exposure.
@Volume_StocksMEDIUMC-2.801s@averageguy62LOW-MEDIUMC-0.481s@StansberryMEDIUM-HIGHB+1.491s · insight@801010athleteMEDIUMC+1.041s@LogicalThesisMEDIUM-HIGHA-0.021s · insight@TradesWithTomMEDIUMC+0.901s
▲Selling Aug21 TEM 65 and 60 cash-secured puts expresses bullish premium capture around current support and gamma setup.
@StratsLabsMEDIUM-HIGHC+2.191s
Direct calls5authors taking explicit directional positions
@Volume_StocksMEDIUMC-2.80
Long TEM after daily confirmed above 54.
@SRxTradesMEDIUM-HIGHC+0.35
Long TEM, targeting 70+
@EchoAnalysisMEDIUMC+0.38
TEM is an easy buy here; safe entry on 50DMA retest.
@MarketMaestro1MEDIUM-HIGHC-1.27
Scale in TEM.
@StratsLabsMEDIUM-HIGHC+2.19
Sold Aug21 TEM 65 and 60 cash-secured puts for premium.
Sellside activity1
Freedom Capital initiate PT 59Initiated coverage on Tempus AI with Hold and $59 PT.
News / data points5discrete events + data quoted by authors
@AIStockSavvyMEDIUMC+0.05
Freedom Capital initiated Tempus AI at Hold with a $59 PT.
@OpenOutcrierMEDIUM-HIGHC
Form 4 filing reported for Tempus AI's Eric Lefkofsky dated Jun 29.
@PrismMarketViewMEDIUM-HIGHC
Tempus AI partnership aims to build a rare-cancer molecular dataset using about 600 sequenced cases.
@PSInvestorLOW-MEDIUMB+1.55
Tempus partnership expands rare cancer molecular dataset and supports the data-moat case.
@OptionsFlowBossLOW-MEDIUMC
Further bullish flow was detected in TEM.
Position disclosures3skin in the game
@Volume_StocksMEDIUMC-2.80
Already in TEM 7/17 55 calls.
@IncomeSharksMEDIUM-HIGHB-0.60
Played TEM breakout and still holding.
@MMMTwealthMEDIUM-HIGHA+1.97
Owns TEM, LLY, CLPT and a small amount of VKTX.
Desk readconvergence assessment
The view is directionally converged around the breakout, but not around why TEM deserves sustained rerating: chart traders dominate the signal count while fundamental bulls lean on AI healthcare and data-moat language. Credibility is mixed: several active bulls have negative trader_score_20, including enrichtrades, Volume_Stocks, MarketMaestro1 and SelzTrades, while the cleanest bear critique comes from a medium-high credibility author. A failed hold above the $58-$60 breakout zone, more insider selling, or evidence that the data moat is not translating into revenue growth would weaken the bull case.
Tracked hypotheses — caliber-scored view · 2026-06-22
🟡 MEDIUM caliber (5)
📈 h5 bull · score 0.61
TEM’s reclaimed moving averages, wedge or cup breakout, and strong relative strength support upside toward 60-70.
- Supporters (14): @EchoAnalysis↗(MEDIUM,2p), @VolumeStocks(MEDIUM,1p), @RockyTSTH↗(LOW-MED,1p), @foycerensever(LOW-MED,1p), @enrichtrades↗(MEDIUM,1p), +9
- Signals: 16 · Max author share: 0.12 · Novelty: stable
- Quote: "Wedge breakout, 50DMA reclaim, and net call premium support continuation." — PeloSwing
📈 h2 bull · score 0.54
TEM’s proprietary clinical data, precision medicine assets, and pharma relationships can become a durable competitive moat.
- Supporters (5): @alc2022↗(MEDIUM-,2p), @MisterInversor↗(MEDIUM,1p), @CaesarCapitalz↗(LOW-MED,2p), @ProfKayaFinance↗(MEDIUM,1p), @EchoAnalysis↗(MEDIUM,1p)
- Signals: 7 · Max author share: 0.29 · Novelty: building
- Quote: "CAI and TEM are framed as racing to dominate biology ontology." — alc2022
📈 h6 bull · score 0.44
Wave-count traders see a much larger TEM move, with 150 as a potential upside target after resistance breaks.
- Supporters (4): @mind1nvestor↗(MEDIUM,1p), @Fibonacci_TA↗(MEDIUM,1p), @EchoAnalysis↗(MEDIUM,1p), @Chartradamus↗(LOW-MED,1p)
- Signals: 4 · Max author share: 0.25 · Novelty: stable
- Quote: "Resistance and 21 EMA break are tied to a Wave 3 target near 150." — mind1nvestor
📈 h7 bull · score 0.35
Call premium, whale call holdings, and dealer gamma above key strikes can mechanically support a near-term rally.
- Supporters (5): @ANajumi(MEDIUM,1p), @MrsZFlow(LOW-MED,1p), @PeloSwing↗(LOW-MED,1p), @ThePupOfWallSt↗(MEDIUM-,1p), @ScorEnterprises↗(LOW-MED,1p)
- Signals: 5 · Max author share: 0.20 · Novelty: building
- Quote: "VEX is stacked above 60 into the 100s, with 50 as the key wall." — A_Najumi
↔️ h10 neutral · score 0.12
TEM’s limited trading history and unclear structure reduce confidence in technical analysis or aggressive entries.
- Supporters (3): @TheWaveCount↗(LOW-MED,1p), @Ahmedalsamel1↗(LOW-MED,2p), @kunal00↗(MEDIUM-,1p)
- Signals: 4 · Max author share: 0.50 · Novelty: building
- ⚠️ Concentration: 50% from @ahmedalsamel1↗ LOW-MEDIUM cred
- Quote: "Limited history and no clean structure lead the author to avoid analysis." — TheWaveCount
⚪ LOW caliber (3)
↔️ h11 neutral · score 0.37
Capital is rotating toward healthcare and financial names while avoiding semis, making TEM part of a preferred sector basket.
- Supporters (2): @TheRonnieVShow↗(MEDIUM-,1p), @ThePupOfWallSt↗(MEDIUM-,1p)
- Signals: 2 · Max author share: 0.50 · Novelty: new
- ⚠️ Concentration: 50% from @theronnievshow↗ MEDIUM-HIGH cred
- Quote: "Healthcare and financial names are preferred while semis are avoided." — TheRonnieVShow
📈 h3 bull · score 0.23
FDA-cleared Tempus AI tools and the Tumor Only xT CDx approval validate the platform and reduce regulatory friction.
- Supporters (2): @IncomeSharks↗(MEDIUM-,1p), @EchoAnalysis↗(MEDIUM,1p)
- Signals: 3 · Max author share: 0.50 · Novelty: stable
- Quote: "FDA approval for Tumor Only xT CDx is presented as reducing regulatory friction." — financespotnews
📈 h4 bull · score 0.12
Revenue scale, narrowing losses, and the BMY partnership show the AI healthcare thesis is gaining business traction.
- Supporters (2): @EchoAnalysis↗(MEDIUM,1p), @CaesarCapitalz↗(LOW-MED,1p)
- Signals: 2 · Max author share: 0.50 · Novelty: stable
- ⚠️ Concentration: 50% from @echoanalysis↗ MEDIUM cred
- Quote: "Revenue scale, lower losses, FDA approval, and BMY partnership are cited as thesis support." — EchoAnalysis
🔴 FLAGGED caliber (3)
📈 h1 bull · score 0.27
TEM can re-rate as a core AI healthcare and biotech platform riding a major health and longevity investment cycle.
- Supporters (5): @MisterInversor↗(MEDIUM,16p), @beachtrades(MEDIUM,3p), @alc2022↗(MEDIUM-,2p), @InvestmentGuru(MEDIUM,1p), @IncomeSharks↗(MEDIUM-,1p)
- Signals: 23 · Max author share: 0.70 · Novelty: building
- ⚠️ Concentration: 70% from @misterinversor↗ MEDIUM cred
- Quote: "Biotech, AI, and deregulation are framed as the start of a major health revolution." — MisterInversor
📈 h8 bull · score 0.02
The open-source digital pathology consortium is a discrete product catalyst that expands TEM’s ecosystem relevance.
- Supporters (1): @FintwitAi↗(LOW-MED,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: stable
- ⚠️ Concentration: 100% from @fintwitai↗ LOW-MEDIUM cred
- Quote: "Tempus launched an open-source digital pathology consortium." — FintwitAi
📉 h9 bear · score 0.02
TEM remains prone to failed rallies, making momentum longs vulnerable despite recurring bullish promotion.
- Supporters (1): @Stockspy1↗(LOW-MED,1p)
- Signals: 1 · Max author share: 1.00 · Novelty: stable
- ⚠️ Concentration: 100% from @stockspy1↗ LOW-MEDIUM cred
- Quote: "TEM is described as repeatedly failing when traders expect continuation." — Stockspy1
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-07-03 · now +0.45 (−1 bearish … +1 bullish)
Who spoke83
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @MisterInversor | C | -0.57 | 16 | +0.48 |
| @enrichtrades | C | -1.64 | 10 | +0.54 |
| @MMMTwealth | A | +1.97 | 9 | +0.42 |
| @Volume_Stocks | C | -2.80 | 9 | +0.40 |
| @MarketMaestro1 | C | -1.27 | 7 | +0.49 |
| @NighthawkTradez | C | +1.24 | 5 | +0.54 |
| @EchoAnalysis | C | +0.38 | 5 | +0.45 |
| @SRxTrades | C | +0.35 | 5 | +0.57 |
| @mark_to_mkt | C | -3.45 | 5 | +0.40 |
| @upsidetrader | C | -1.12 | 5 | +0.45 |
| @IncomeSharks | B | -0.60 | 5 | +0.55 |
| @Pablo01618 | A | -1.53 | 4 | +0.39 |
| @SixSigmaCapital | B | -0.48 | 4 | -0.20 |
| @jrouldz | B | -0.37 | 3 | +0.38 |
| @PSInvestor | B | +1.55 | 3 | +0.40 |
| @TradesWithTom | C | +0.90 | 3 | +0.25 |
| @averageguy62 | C | -0.48 | 3 | +0.08 |
| @TheRonnieVShow | C | -0.15 | 2 | +0.40 |
| @beach_trades | C | -2.81 | 2 | +0.42 |
| @ZaStocks | C | -0.55 | 2 | +0.55 |
| @davevermilion | A | -2.03 | 2 | +0.27 |
| @LogicalThesis | A | -0.02 | 2 | +0.25 |
| @AIStockSavvy | C | +0.05 | 2 | +0.30 |
| @OptionsFlowBoss | C | · | 2 | +0.45 |
| @R1chardMaur1ce | C | -0.17 | 2 | +0.53 |
Recent signals30of 183 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-03 | @JoshTradeOption | +0.45 | Tempus AI bullish thesis cites 36% revenue growth, 40% platform growth and analyst PT range. | — | tweet ↗ |
| 2026-07-02 | @Volume_Stocks | +0.25 | Mentions SNOW and TEM as preferred names in reply. | — | tweet ↗ |
| 2026-07-02 | @enrichtrades | +0.30 | Weekly recap lists realized gains and sell into strength lesson. | — | tweet ↗ |
| 2026-07-02 | @StratsLabs | +0.55 | Sold Aug21 TEM 65 and 60 cash-secured puts for premium. — Author enters cash-secured puts with bullish chart/gamma setup and profit plan. | — | tweet ↗ |
| 2026-07-02 | @Sir_Kory | +0.00 | Lists high short-float stocks sourced from Finviz. | — | tweet ↗ |
| 2026-07-02 | @averageguy62 | -0.25 | Out of TEM — Author states TEM out, indicating an exit. | — | tweet ↗ |
| 2026-07-02 | @MisterInversor | +0.55 | Says biotech next 5 years will be wild, with TEM and CRSP above $60 and IBRX near $10. | — | tweet ↗ |
| 2026-07-02 | @dafster17 | +0.15 | Says TEM is hitting a huge technical spot, chart context required. | — | tweet ↗ |
| 2026-07-02 | @mark_to_mkt | +0.15 | FIG double bottom pattern with strong fundamentals and cash on hand. | — | tweet ↗ |
| 2026-07-02 | @Volume_Stocks | +0.50 | Reports calls went over 100% and other positions have been hot. | — | tweet ↗ |
| 2026-07-02 | @OpenOutcrier | -0.20 | Reports Form 4 filing by Tempus AI's Eric Lefkofsky for Jun 29. | — | tweet ↗ |
| 2026-07-02 | @wallstengine | +0.25 | AI-built healthcare fund performance recap with realized gains since June 3. | — | tweet ↗ |
| 2026-07-02 | @MisterInversor | +0.65 | Bullish on health/biotech firms due to expected health issues over coming months/years. | — | tweet ↗ |
| 2026-07-01 | @Pablo01618 | +0.60 | Reports closing calls/positions up 1000%, 2200%, and 780%. | -2.2% | tweet ↗ |
| 2026-07-01 | @Abim4el_Carlos | +0.65 | Bullish thesis on Tempus AI health data and pharma partnerships. | -2.2% | tweet ↗ |
| 2026-07-01 | @Abim4el_Carlos | +0.65 | Author likes Tempus as an AI-in-healthcare winner. | -2.2% | tweet ↗ |
| 2026-07-01 | @enrichtrades | +0.80 | Breakout gives clear path to 70+. | -2.2% | tweet ↗ |
| 2026-07-01 | @RedDogT3 | +0.40 | Past-tense recap that HIMS and TEM paid actively over two weeks. | -2.2% | tweet ↗ |
| 2026-07-01 | @MisterInversor | +0.45 | Anthropic Claude Science launch framed as catalyst for health/biotech sector. | -2.2% | tweet ↗ |
| 2026-07-01 | @OptionsFlowBoss | +0.55 | Reports further bullish flow detected in TEM. | -2.2% | tweet ↗ |
| 2026-07-01 | @IncomeSharks | +0.65 | Says played TEM breakout and still holding, hopes it signals bio-health/genome sector move. | -2.2% | tweet ↗ |
| 2026-07-01 | @upsidetrader | +0.60 | Reports TEM hitting targets after the move. | -2.2% | tweet ↗ |
| 2026-07-01 | @QueTraders | +0.00 | Compares SPY 0DTE with TEM weekly swings. | -2.2% | tweet ↗ |
| 2026-07-01 | @jrouldz | +0.10 | Checking back on setups with chart context but no trade intent. | -2.2% | tweet ↗ |
| 2026-07-01 | @IncomeSharks | +0.35 | Notes TEM breaking past 60 with resistance not until 75 range. | -2.2% | tweet ↗ |
| 2026-07-01 | @SelzTrades | +0.50 | Let it load up for the next leg up. — Says TEM moved from $55 to $62 and expects next leg up after loading. | -2.2% | tweet ↗ |
| 2026-07-01 | @MisterInversor | +0.55 | Bullish human health revolution thematic basket. | -2.2% | tweet ↗ |
| 2026-07-01 | @BeatTheInsider | +0.25 | Trump disclosed bought and sold stock trades; max ticker cap keeps first six. | -2.2% | tweet ↗ |
| 2026-07-01 | @Stansberry | -0.20 | Says Tempus AI had value but crossed risk limit; emphasizes trailing stops and downside protection. | -2.2% | tweet ↗ |
| 2026-07-01 | @ProfKayaFinance | +0.35 | Lists strong percent gains for META, PLTR, AXON and TEM. | -2.2% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.